Erratum to The 2015 CUA-CUOG Guideline for the management of castration-resistant prostate cancer (CRPC) (Can Urol Assoc J, (2015) 9, (90-96)), 10.5489/cuaj.2526;The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC)

Journal of the Canadian Urological Association

Volumn 9, Issue 3-4APRIL, 2015, Pages 90-96

  Saad, Fred ^a   Chi, Kim N ^b   Finelli, Antonio ^c   Hotte, Sebastien J ^d   Izawa, Jonathan ^e   Kapoor, Anil ^d   Kassouf, Wassim ^f   Loblaw, Andrew ^c   North, Scott ^b,i   Rendon, Ricardo ^g   So, Alan ^h   Usmani, Nawaid ⁱ   Vigneault, Eric ^j   Fleshner, Neil E ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j LAVAL UNIVERSITY   (Canada)

more..

Author keywords

Castration resistant; Prostate cancer

Indexed keywords

EID: 84928041587     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.3493     Document Type: Erratum

References (36)

1. Mohler JL, Gregory CW, Ford OH, 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8. http://dx.doi.org/10.1158/1078-0432.CCR-1146-03.
2. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59. http://dx.doi.org/10.1200/JCO.2007.12.4487.
3. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918-25. http://dx.doi.org/10.1200/ JCO.2005.01.529.
4. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583) J Clin Oncol 2004;22:1025-33. http://dx.doi.org/10.1200/JCO.2004.06.037.
5. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014;66:815-25. http://dx.doi.org/10.1016/j.eururo.2014.02.056.
6. Sternberg CN, Castellano D, Daugaard G, et al. Abiraterone acetate for patients with metastatic castrationresistant prostate cancer progressing after chemotherapy: Final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol 2014;15:1263-8. http://dx.doi.org/10.1016/S1470-2045(14)70417-6.
7. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33. http://dx.doi.org/10.1056/NEJMoa1405095.
8. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787. http://dx.doi.org/10.1126/science.1168175.
9. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97. http://dx.doi.org/10.1056/NEJMoa1207506.
10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. http://dx.doi.org/10.1056/ NEJMoa040720.
11. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. http://dx.doi.org/10.1056/NEJMoa041318.
12. Michels J, Montemurro T, Murray N, et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter? Cancer 2006;106:1041-6. http://dx.doi.org/10.1002/cncr.21695.
13. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147. http://dx.doi.org/10.1016/S0140-6736(10)61389-X.
14. Oh WK, Manola J, Babcic V, et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67:1235-40. http://dx.doi.org/10.1016/j.urology.2006.01.006.
15. Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: A population based analysis [abstract #196]. 2008 ASCO Genitourinary Symposium; 2008.
16. Eymard J, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: A retrospective multicentre study. BJU Int 2010;106:974-8. http://dx.doi.org/10.1111/j.1464-410X.2010.09296.x.
17. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23. http://dx.doi.org/10.1056/NEJMoa1213755.
18. Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892. http://dx.doi. org/10.1002/cncr.20056
19. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64. http://dx.doi.org/10.1056/NEJMoa041943.
20. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55. http://dx.doi.org/10.1056/ NEJMoa010845.
21. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008–12. http://dx.doi.org/10.1097/01.ju.0000063820.94994.95.
22. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen- deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55. http://dx.doi.org/10.1056/NEJMoa0809003.
23. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82. http://dx.doi.org/10.1093/jnci/djh141.
24. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double- blind study. Lancet 2011;377:813. http://dx.doi.org/10.1016/S0140-6736(10)62344-6.
25. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study. J Clin Oncol 2010;28:S15.
26. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099. http://dx.doi.org/10.1200/JCO.2009.25.0597.
27. Saad F, Hotte SJ, North SA, et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer who relapsed on or within six months of 1st-line docetaxel therapy. Can Urol Assoc J 2008;2:568.
28. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castrationresistant prostate cancer: results of a phase 3, randomised, placebo- controlled trial. Lancet 2012;379:39-46. http://dx.doi.org/10.1016/S0140- 6736(11)61226-9.
29. Storlie JA, Buckner JC, Wiseman GA, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96-100. http://dx.doi.org/10.1002/1097-0142(19950701)76:1<96::AID-CNCR2820760114>3.0.CO;2-E.
30. Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol 2006;13:3335-9.
31. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled trial. Semin Oncol 1993;20:38-43.
32. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium (89) chloride versus palliative local field radio-therapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519-26. http://dx.doi. org/10.1016/S0302-2838(03)00364-6.
33. Loblaw DA, Mitera G, Ford M, et al. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys 2012;84:312-7. http://dx.doi.org/10.1016/j.ijrobp.2012.01.014.
34. Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 2009;103:434. http://dx.doi.org/10.1111/j.1464-410X.2008.08249.x.
35. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 2009;27:5061. http://meeting.ascopubs.org/cgi/content/short/27/15S/5061.
36. Chi KN, Hotte JS, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:4247-54. http://dx.doi.org/10.1200/JCO.2009.26.8771.